Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
3D Investment Partners said on April 28 that it is “deeply disappointed” by Toho Holdings’ decision to seek shareholder approval at its June general meeting to trigger takeover defense measures. The fund, which has indicated its intention to make a…
To read the full story
Related Article
- 3D Seeks Injunction against Toho’s Poison Pill
August 18, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Toho Shareholders Approve Trigger for 3D Defense Measures
June 29, 2026
- 3D Slams Toho’s Info Requests as Bid to Justify Defense Measures
April 21, 2026
- 3D Says Toho Share Purchase Is Long-Term Investment, Not Attempt at Control
February 5, 2026
- Toho Seeks Additional Disclosure from 3D over Proposed Share Purchases
January 26, 2026
- 3D Plans to Lift Toho Stake to Up to 27%
January 19, 2026
- Toho Adopts Poison Pill in Response to 3D’s Rising Stake
November 4, 2025
BUSINESS
- Recordati Urges Rethink of Zero-Premium Rule on Cost Disclosure
August 31, 2026
- Sumitomo Pharma Goes Global with Adjuvants, Targets 100 Billion Yen
August 31, 2026
- Shionogi to Get US$36.9 Million as US Govt Procures Fetroja
August 31, 2026
- Daiichi’s CD25-Directed ADC DS1025 Enters Clinic
August 31, 2026
- Bayer Files Kerendia in Japan for Broader CKD Use
August 31, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…